Education
Level 1: Physique EssentialsApplied Hypertrophy Optimization (AHO)Female Physique Module
Training Programs
X-Frame ProgramHourglass Program
Coaching
Apply for Coaching
Community
J3U Hub (Free)Applied LabAffiliate Program
More
BlogMerch
Student portal Join Now
‹ All articles
Bodybuilding

Episode 33: Prophylactic Series: Why Telmisartan in Enhanced Competitors?

Episode 33: Prophylactic Series: Why Telmisartan in Enhanced Competitors?

In this episode of J3 University, Luke and I discuss the risk of PED usage and how blood pressure medications serve as a hard reduction strategy. All blood pressure medications are covered and specially answering why Telmisartan is spoken about more frequently. 

Timestamps

NPC Nationals and Pro Card Wins- 00:00:08

Enhanced Bodybuilder Risk- 00:03:10

Renin-angiotensin-aldosterone system, Classes of Medication- 00:07:52

ARB vs ACE Inhibitors- 00:13:31

Telmisartan Actions/Benefits- 00:15:15

Blood viscosity/blood dump, Improvement in lab work- 00:19:14

Access to medication- 00:24:36

Deploying for reduction in Water retention- 00:29:46

Where to find more info- 00:34:00

Episode Available On: YouTube, Spotify, Google Play, iTunes

Like, Share, Subscribe

LINK in BIO
#J3University

Take the guesswork out of your physique

J3U Level 1 gives you the full science based system for training, nutrition, and PED strategy. Or join the free J3U Hub and start learning today.

More from Bodybuilding
Bodybuilding

Up the Protein Intake for Enhanced Bodybuilders!

I have heard it all and done it all coming up through the pro ranks. Personally, I have done the massive protein intake …

John JewettMarch 3, 2024
Bodybuilding

Episode 113: Cardio to Retain Muscle During Fat Loss

In the third installation of this series, John and Luke dive into cardio and how to approach and maximize your cardio st…

John JewettFebruary 19, 2024
Bodybuilding

Episode 110: Creating the Worst Physique Coach

In this episode, John and Luke discuss the qualities of an all-time bad physique coach, while also addressing points tha…

John JewettFebruary 19, 2024